UY37003A - Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion - Google Patents
Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacionInfo
- Publication number
- UY37003A UY37003A UY0001037003A UY37003A UY37003A UY 37003 A UY37003 A UY 37003A UY 0001037003 A UY0001037003 A UY 0001037003A UY 37003 A UY37003 A UY 37003A UY 37003 A UY37003 A UY 37003A
- Authority
- UY
- Uruguay
- Prior art keywords
- compositions
- methods
- cytoquine
- immunor
- regulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Abstract
Esta descripción proporciona composiciones de anticuerpo injertadas con citoquina, incluyendo, por ejemplo, constructos injertados que se unen a y estimulan la señalización intracelular por un miembro de la super-familia del receptor de interleucina, y estimulan la señalización. Composiciones proporcionadas encuentran uso en mejora de respuestas de células anti-inflamatorias, y relativamente reducen efectos pro-inflamatorios en el tratamiento, mejora, prevención de trastornos relacionados con el sistema inmune que pueden ser contrarrestados con una respuesta anti-inflamatoria aumentada. Se proporcionan polinucleótidos y vectores que codifican tales moléculas y células huésped capaces de producir moléculas, así como también métodos de fabricación y uso de composiciones.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562263008P | 2015-12-04 | 2015-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY37003A true UY37003A (es) | 2017-06-30 |
Family
ID=57543103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001037003A UY37003A (es) | 2015-12-04 | 2016-12-01 | Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion |
Country Status (25)
Country | Link |
---|---|
US (3) | US10144768B2 (es) |
EP (1) | EP3383891A1 (es) |
JP (2) | JP6794448B2 (es) |
KR (2) | KR102213790B1 (es) |
CN (1) | CN108602870A (es) |
AR (1) | AR106908A1 (es) |
AU (1) | AU2016362777B2 (es) |
BR (1) | BR112018010937A2 (es) |
CA (1) | CA3006477A1 (es) |
CL (1) | CL2018001427A1 (es) |
CO (1) | CO2018005678A2 (es) |
CU (1) | CU20180047A7 (es) |
EA (1) | EA201891341A1 (es) |
EC (1) | ECSP18041733A (es) |
IL (1) | IL259529A (es) |
MA (1) | MA43372A (es) |
MX (1) | MX2018006778A (es) |
PE (1) | PE20181358A1 (es) |
PH (1) | PH12018501160A1 (es) |
RU (1) | RU2018124307A (es) |
SA (1) | SA518391711B1 (es) |
SG (1) | SG11201804259UA (es) |
TW (1) | TW201726716A (es) |
UY (1) | UY37003A (es) |
WO (1) | WO2017093947A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200362058A1 (en) * | 2017-05-24 | 2020-11-19 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use |
US20200270334A1 (en) * | 2017-05-24 | 2020-08-27 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
WO2018215937A1 (en) * | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
CN109521192B (zh) * | 2018-11-27 | 2021-07-13 | 柏荣诊断产品(上海)有限公司 | 一种提高胶乳比浊试剂检测灵敏度的方法 |
US10858412B2 (en) * | 2019-03-06 | 2020-12-08 | Deka Biosciences, Inc. | Antibody variable domain regions fused to IL-10 variant molecules |
WO2020252082A1 (en) * | 2019-06-10 | 2020-12-17 | Millennium Pharmaceuticals, Inc. | Cell culture methods and compositions for antibody production |
CN114302891A (zh) * | 2019-07-08 | 2022-04-08 | 普罗根有限公司 | 新的il-10变体蛋白及其用途 |
CN110472294B (zh) * | 2019-07-19 | 2022-09-30 | 河南科技大学 | 一种嫁接涡旋光束的掩模板的设计方法 |
JP2023550459A (ja) | 2020-11-23 | 2023-12-01 | ノバルティス アーゲー | 抗体構築物の発現技術 |
EP4330383A1 (en) | 2021-04-29 | 2024-03-06 | Novartis AG | Hypersialylating cells |
WO2023078245A1 (zh) * | 2021-11-02 | 2023-05-11 | 广东菲鹏制药股份有限公司 | Il10单体融合蛋白及其应用 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
WO1992010591A1 (en) | 1990-12-14 | 1992-06-25 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
CA2196200A1 (en) | 1994-07-29 | 1996-02-15 | Michael Joseph Browne | Novel compounds |
WO1996018412A1 (en) * | 1994-12-12 | 1996-06-20 | Beth Israel Hospital Association | Chimeric cytokines and uses thereof |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
JP2002505086A (ja) | 1998-02-25 | 2002-02-19 | レキシジェン ファーマシューティカルズ コーポレイション | 抗体ベースの融合タンパク質の循環半減期の増強 |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US7279462B1 (en) | 1998-04-27 | 2007-10-09 | Nevagen Llc | Somatic transgene immunization and related methods |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
WO2002044197A2 (en) | 2000-12-01 | 2002-06-06 | Fish Eleanor N | Cytokine receptor binding peptides |
US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
ATE544785T1 (de) | 2000-12-05 | 2012-02-15 | Alexion Pharma Inc | Rationell entworfene antikörper |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
ES2301794T3 (es) | 2002-04-09 | 2008-07-01 | The Curators Of The University Of Missouri | Tratamiento de la diabetes de tipo 1, antes y despues de la expresion de marcadores de predisposicion. |
NZ536054A (en) * | 2002-04-09 | 2009-10-30 | Scripps Research Inst | Motif-grafted hybrid polypeptides and uses thereof |
US8603472B2 (en) * | 2002-04-09 | 2013-12-10 | The Curators Of The University Of Missouri | Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide |
US20050008625A1 (en) | 2003-02-13 | 2005-01-13 | Kalobios, Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
CA2520865A1 (en) | 2003-03-31 | 2004-10-21 | The Brigham And Women's Hospital, Inc. | Zwitterionic immunomodulators for the treatment of asthma and allergy |
WO2004108078A2 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals Inc. | Rationally designed antibodies |
AU2005207003C1 (en) | 2004-01-20 | 2013-06-13 | Humanigen, Inc. | Antibody specificity transfer using minimal essential binding determinants |
ES2744149T3 (es) | 2004-11-16 | 2020-02-21 | Humanigen Inc | Intercambio de casetes de la región variable de la inmunoglobulina |
AU2008346734A1 (en) | 2008-01-03 | 2009-07-16 | The Scripps Research Institute | Antibody targeting through a modular recognition domain |
MX2011008936A (es) * | 2009-02-24 | 2011-09-21 | Alexion Pharma Inc | Anticuerpos que contienen peptidos terapeuticos mimeticos de tpo/epo. |
JP5764127B2 (ja) | 2009-08-17 | 2015-08-12 | ロシュ グリクアート アーゲー | 標的化イムノコンジュゲート |
AU2010306677B2 (en) | 2009-10-15 | 2013-05-23 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
CN102711829B (zh) | 2009-11-30 | 2016-03-16 | 生物测试股份公司 | 治疗系统性红斑狼疮(sle)的人源化抗il-10抗体 |
WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
WO2012045334A1 (en) * | 2010-10-05 | 2012-04-12 | Synthon Bv | Biologically active il-10 fusion proteins |
AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
PE20140303A1 (es) | 2011-02-10 | 2014-03-22 | Roche Glycart Ag | Polipeptidos interleuquina-2 mutantes |
CA2824252A1 (en) | 2011-02-10 | 2012-08-16 | Roche Glycart Ag | Improved immunotherapy |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
WO2013106485A2 (en) * | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
WO2013106489A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
SG10201800535XA (en) | 2012-08-07 | 2018-02-27 | Roche Glycart Ag | Composition comprising two antibodies engineered to have reduced and increased effector function |
BR112015002085A2 (pt) * | 2012-08-08 | 2017-12-19 | Roche Glycart Ag | proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
CN105073781A (zh) | 2013-01-11 | 2015-11-18 | 加州生物医学研究所 | 牛融合抗体 |
EP2964750B1 (en) * | 2013-03-08 | 2019-03-06 | The Curators of the University of Missouri | Compositions for use in the treatment of type 1 diabetes |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
EP3693397A1 (en) | 2013-07-11 | 2020-08-12 | The Scripps Research Institute | Coiled coil immunoglobulin fusion proteins and compositions thereof |
EP3022224A2 (en) | 2013-07-18 | 2016-05-25 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
CN105814074B (zh) | 2013-07-18 | 2020-04-21 | 图鲁斯生物科学有限责任公司 | 具有超长互补决定区的人源化抗体 |
MX370283B (es) | 2014-02-06 | 2019-12-09 | Hoffmann La Roche | Proteinas de fusion de interleucina-2 y usos de las mismas. |
RU2016135788A (ru) * | 2014-02-06 | 2018-03-07 | Ф.Хоффманн-Ля Рош Аг | Иммуноконъюгаты интерлейкина 10 |
-
2016
- 2016-12-01 CA CA3006477A patent/CA3006477A1/en not_active Abandoned
- 2016-12-01 KR KR1020187018601A patent/KR102213790B1/ko active IP Right Grant
- 2016-12-01 MX MX2018006778A patent/MX2018006778A/es unknown
- 2016-12-01 WO PCT/IB2016/057283 patent/WO2017093947A1/en active Application Filing
- 2016-12-01 CN CN201680080872.0A patent/CN108602870A/zh active Pending
- 2016-12-01 RU RU2018124307A patent/RU2018124307A/ru not_active Application Discontinuation
- 2016-12-01 SG SG11201804259UA patent/SG11201804259UA/en unknown
- 2016-12-01 EA EA201891341A patent/EA201891341A1/ru unknown
- 2016-12-01 MA MA043372A patent/MA43372A/fr unknown
- 2016-12-01 KR KR1020217003359A patent/KR20210016479A/ko active Application Filing
- 2016-12-01 AU AU2016362777A patent/AU2016362777B2/en not_active Ceased
- 2016-12-01 CU CUP2018000047A patent/CU20180047A7/es unknown
- 2016-12-01 BR BR112018010937-1A patent/BR112018010937A2/pt not_active IP Right Cessation
- 2016-12-01 PE PE2018001044A patent/PE20181358A1/es unknown
- 2016-12-01 JP JP2018528732A patent/JP6794448B2/ja active Active
- 2016-12-01 UY UY0001037003A patent/UY37003A/es not_active Application Discontinuation
- 2016-12-01 US US15/367,003 patent/US10144768B2/en active Active
- 2016-12-01 EP EP16810069.1A patent/EP3383891A1/en active Pending
- 2016-12-02 TW TW105139831A patent/TW201726716A/zh unknown
- 2016-12-02 AR ARP160103699A patent/AR106908A1/es unknown
-
2018
- 2018-05-22 IL IL259529A patent/IL259529A/en unknown
- 2018-05-28 CL CL2018001427A patent/CL2018001427A1/es unknown
- 2018-05-29 CO CONC2018/0005678A patent/CO2018005678A2/es unknown
- 2018-05-31 SA SA518391711A patent/SA518391711B1/ar unknown
- 2018-06-01 PH PH12018501160A patent/PH12018501160A1/en unknown
- 2018-06-15 EC ECIEPI201841733A patent/ECSP18041733A/es unknown
- 2018-10-18 US US16/163,857 patent/US11136366B2/en active Active
-
2020
- 2020-11-11 JP JP2020188307A patent/JP2021040637A/ja active Pending
-
2021
- 2021-08-26 US US17/458,028 patent/US20220127321A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY37003A (es) | Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion | |
CU20170045A7 (es) | Anticuerpos agonistas de anti-gitr y composiciones de los mismos | |
CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
CL2016002004A1 (es) | Anticuerpos anti-jagged1 y métodos de uso | |
CY1122956T1 (el) | Αντισωματα εναντι αντιγονου 2 των δενδριτικων κυτταρων του αιματος και χρησεις αυτων | |
BR112019011450A2 (pt) | células naturais killer modificadas e uso das mesmas | |
ECSP17005276A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
UY36154A (es) | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos | |
AR099289A1 (es) | Proteínas de fusión de interleucina-2 y usos de las mismas | |
NZ761188A (en) | Antibody molecules to tim-3 and uses thereof | |
AR092188A1 (es) | ANTICUERPOS HUMANOS PARA GFRa3 Y METODOS PARA SU USO | |
UY37738A (es) | Proteínas injertadas de anticuerpo-citoquina y métodos de uso para trastornos inmunes relacionados | |
CL2018000103A1 (es) | Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana | |
CL2016002088A1 (es) | Anticuerpos monoclonales biespecificos contra il-13/il-17; ácido nucleico; célula huésped; método de producción del anticuerpo; inmunoconjugados; formulación farmacéutica; y usos de los anticuerpos biespecíficios para el tratamiento del asma moderada a severa y/o asma eosinofílica. | |
CL2016000438A1 (es) | Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica | |
PE20170192A1 (es) | Mutagenesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las meloid tipo 1 (trem-1) para reducir la viscosidad | |
DOP2018000019A (es) | Inmunoconjugados de il22 | |
UY37281A (es) | Variantes de gm-csf y métodos de uso | |
AR105945A1 (es) | Composiciones y métodos usados para aumentar la respuesta inmune y terapia del cáncer | |
AR101592A1 (es) | Tratamiento de cáncer usando un receptor quimérico de antígeno cd123 | |
AR103227A1 (es) | Anticuerpos anti-csf1r para el tratamiento de svp | |
CL2012001309A1 (es) | Anticuerpos humanizados contra el receptor alfa de la interleucina 22 (il-22ra) humana; polinucleotido que codifica tanto la cadena pesada como la cadena liviana de dicho anticuerpo; vector y celula hospedera que comprende dicho polinucleotido; composicion farmaceutica que comprende el anticuerpo; uso del anticuerpo para tratar soriasis, artritis soriatica o dermatitis atópica. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20221212 |